UBS has lowered its price target on Colgate-Palmolive (NYSE: CL) to $106 from $109 while maintaining a Buy rating, citing valuation discipline and potential upside of roughly 22%. The company’s strong pricing execution and demand for personal care products support earnings growth, with a balanced outlook as shares approach fair value.

Investors are interested in Colgate’s next earnings update for insights on input cost trends and competitive dynamics. Despite Colgate’s solid performance in oral care and pet nutrition, UBS suggests other AI stocks may offer greater upside potential with less downside risk. A free report on the best short-term AI stock is available.

Colgate’s consistent performance in oral care and pet nutrition, along with improving volumes in emerging markets, contribute to a more balanced outlook. Margin recovery efforts and disciplined brand investments are expected to support earnings growth through the year. Analysts see potential in Colgate as an investment, but highlight other AI stocks for greater upside potential.

Read more at Yahoo Finance: UBS Trims Colgate (CL) Price Target, Maintains Buy Rating